600276 恒瑞医药
已收盘 04-19 15:00:00
资讯
新帖
简况
恒瑞“变质”
虎嗅APP · 11:43
恒瑞“变质”
恒瑞医药获融资买入0.76亿元,近三日累计买入3.48亿元
金融界 · 08:14
恒瑞医药获融资买入0.76亿元,近三日累计买入3.48亿元
易方达基金杨桢霄旗下易方达医疗一季报最新持仓,重仓恒瑞医药
证券之星 · 06:21
易方达基金杨桢霄旗下易方达医疗一季报最新持仓,重仓恒瑞医药
易方达基金陈皓旗下易方达品质动能三年持有混合A一季报最新持仓,重仓恒瑞医药
证券之星 · 06:21
易方达基金陈皓旗下易方达品质动能三年持有混合A一季报最新持仓,重仓恒瑞医药
恒瑞医药业绩双增:集采阴霾渐消,创新转型成果显现
观察者网 · 04-19 18:56
恒瑞医药业绩双增:集采阴霾渐消,创新转型成果显现
恒瑞医药04月19日遭主力抛售1.26亿元 环比减少43.87%
自选股智能写手 · 04-19 15:17
恒瑞医药04月19日遭主力抛售1.26亿元 环比减少43.87%
直接明牌爆雷!收购遇阻,大牛股高新发展连续两日跌停
格隆汇 · 04-19 10:44
直接明牌爆雷!收购遇阻,大牛股高新发展连续两日跌停
恒瑞医药4月18日获融资净买入1.22亿元 两市排名第1
自选股智能写手 · 04-19 10:00
恒瑞医药4月18日获融资净买入1.22亿元 两市排名第1
中信海直、恒瑞医药等股获融资净买入超1亿元
证券时报网 · 04-19 09:36
中信海直、恒瑞医药等股获融资净买入超1亿元
恒瑞医药4月18日遭北向资金减持137.11万股
自选股智能写手 · 04-19 09:30
恒瑞医药4月18日遭北向资金减持137.11万股
恒瑞医药(600276)2024年一季报简析:营收净利润同比双双增长
证券之星 · 04-19 06:21
恒瑞医药(600276)2024年一季报简析:营收净利润同比双双增长
银华基金马君旗下银华中证创新药产业ETF一季报最新持仓,重仓恒瑞医药
证券之星 · 04-19 06:16
银华基金马君旗下银华中证创新药产业ETF一季报最新持仓,重仓恒瑞医药
恒瑞医药:公司第4款产品获得美国FDA快速通道资格认定
证券时报·e公司 · 04-18 21:03
恒瑞医药:公司第4款产品获得美国FDA快速通道资格认定
“创新药一哥”恒瑞医药2023年业绩止跌回升,仿制药收入滑坡,海外BD道阻且长 | 看财报
钛媒体 · 04-18 17:43
“创新药一哥”恒瑞医药2023年业绩止跌回升,仿制药收入滑坡,海外BD道阻且长 | 看财报
恒瑞医药:2023年度暨2024年第一季度业绩说明会公告
金融界 · 04-18 17:42
恒瑞医药:2023年度暨2024年第一季度业绩说明会公告
恒瑞医药:子公司获得药物临床试验批准通知书,将开展SHR-3276注射液的临床试验
金融界 · 04-18 17:15
恒瑞医药:子公司获得药物临床试验批准通知书,将开展SHR-3276注射液的临床试验
恒瑞医药(600276)3月31日股东户数44.05万户,较上期减少5.31%
证券之星 · 04-18 17:02
恒瑞医药(600276)3月31日股东户数44.05万户,较上期减少5.31%
恒瑞医药(600276.SH):注射用SHR-A2102获美国FDA授予快速通道资格
智通财经网 · 04-18 16:57
恒瑞医药(600276.SH):注射用SHR-A2102获美国FDA授予快速通道资格
恒瑞医药(600276.SH):HRS2398缓释片临床试验获批
智通财经网 · 04-18 16:53
恒瑞医药(600276.SH):HRS2398缓释片临床试验获批
加载更多
公司概况
公司名称:
江苏恒瑞医药股份有限公司
所属行业:
医药制造业
上市日期:
2000-10-18
主营业务:
江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。
发行价格:
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":41.68,"timestamp":1713510000000,"preClose":42.35,"halted":0,"volume":38425460,"delay":0,"floatShares":6379000000,"shares":6379000000,"eps":0.6949,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.67,"latestTime":"04-19 15:00:00","open":42,"high":42.34,"low":41.22,"amount":1602000000,"amplitude":0.0264,"askPrice":41.69,"askSize":58,"bidPrice":41.68,"bidSize":157,"shortable":0,"etf":0,"ttmEps":0.6949,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"adjPreClose":42.35,"symbolType":"stock","openAndCloseTimeList":[[1713490200000,1713497400000],[1713502800000,1713510000000]],"highLimit":46.59,"lowLimit":38.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6379002274,"pbRate":6.35,"roa":"--","roe":"3.33%","epsLYR":0.68,"committee":0.493671,"marketValue":265877000000,"floatMarketCap":265877000000,"peRate":59.979855,"changeRate":-0.0158,"turnoverRate":0.006,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-04-22。"},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2428606617","title":"恒瑞“变质”","url":"https://stock-news.laohu8.com/highlight/detail?id=2428606617","media":"虎嗅APP","top":-1,"share":"https://www.laohu8.com/m/news/2428606617?lang=zh_cn&edition=full","pubTime":"2024-04-20 11:43","pubTimestamp":1713584594,"startTime":"0","endTime":"0","summary":"似乎经过抢救,恒瑞就能重获新生。#01政策压力增大恒瑞面临的压力首先来自政策的变化。恒瑞医药2021年6月之后的大幅下跌就是集采导致的。2011年6月14日,恒瑞发布公告,其研制的国家一类新药“艾瑞昔布片及原料”获得国家食品药品监督管理局颁发的《新药证书》及《药品注册批件》。恒瑞开始在创新药领域“一骑绝尘”,创新药一哥的地位就此奠定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404201145178b3d8739&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404201145178b3d8739&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428154836","title":"恒瑞医药获融资买入0.76亿元,近三日累计买入3.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428154836","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428154836?lang=zh_cn&edition=full","pubTime":"2024-04-20 08:14","pubTimestamp":1713572096,"startTime":"0","endTime":"0","summary":"4月19日,沪深两融数据显示,恒瑞医药获融资买入额0.76亿元,居两市第107位,当日融资偿还额0.71亿元,净买入513.04万元。最近三个交易日,17日-19日,恒瑞医药分别获融资买入0.56亿元、2.15亿元、0.76亿元。融券方面,当日融券卖出3.02万股,净买入1.09万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404200817088797ad8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404200817088797ad8e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428697155","title":"易方达基金杨桢霄旗下易方达医疗一季报最新持仓,重仓恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2428697155","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428697155?lang=zh_cn&edition=full","pubTime":"2024-04-20 06:21","pubTimestamp":1713565293,"startTime":"0","endTime":"0","summary":"证券之星消息,4月20日易方达基金旗下杨桢霄管理的易方达医疗保健行业混合型基金公布一季报,近1年净值增长率-12.86%。与上一季度相比,该基金前十大重仓股新增诺泰生物,泰格医药;并对恒瑞医药增仓110.22万股,为该基金第一大重仓股;南微医学,爱博医疗等退出前十大重仓股;详细数据如下:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240420062335879763be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240420062335879763be&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428971536","title":"易方达基金陈皓旗下易方达品质动能三年持有混合A一季报最新持仓,重仓恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2428971536","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428971536?lang=zh_cn&edition=full","pubTime":"2024-04-20 06:21","pubTimestamp":1713565290,"startTime":"0","endTime":"0","summary":"证券之星消息,4月20日易方达基金旗下陈皓管理的易方达品质动能三年持有期混合型基金公布一季报,近1年净值增长率-19.22%。与上一季度相比,该基金前十大重仓股新增桐昆股份,新五丰,华电国际;其中恒瑞医药持仓占比4.49%,为该基金第一大重仓股;宝信软件,抚顺特钢,贵州茅台等退出前十大重仓股;详细数据如下:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240420062337879763c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240420062337879763c7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428378396","title":"恒瑞医药业绩双增:集采阴霾渐消,创新转型成果显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2428378396","media":"观察者网","top":-1,"share":"https://www.laohu8.com/m/news/2428378396?lang=zh_cn&edition=full","pubTime":"2024-04-19 18:56","pubTimestamp":1713524186,"startTime":"0","endTime":"0","summary":"为规避集采带来的影响,近年来恒瑞医药一直在调整策略,加码创新转型和国际化。事实上,创新转型已经成为医药行业的必然趋势,而恒瑞医药在这一方面的投入和布局也已经开始显现成效。恒瑞医药在过去几年中持续加强其在商业化方面的努力,成功推出了一系列创新药物。在专利申请和维持方面,恒瑞医药同样展现出了强劲的增长势头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191858398b3ad068&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191858398b3ad068&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428689847","title":"恒瑞医药04月19日遭主力抛售1.26亿元 环比减少43.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428689847","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428689847?lang=zh_cn&edition=full","pubTime":"2024-04-19 15:17","pubTimestamp":1713511049,"startTime":"0","endTime":"0","summary":"04月19日, 恒瑞医药股价跌1.58%,报收41.68元,成交金额16.02亿元,换手率0.60%,振幅2.64%,量比1.28。恒瑞医药今日主力资金净流出1.26亿元,连续4日净流出,上一交易日主力净流出2.24亿元,今日环比减少43.87%。|04月19日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|百通能源|9.19%|#|通源石油|7.28%|#|立航科技|7.02%|#|贝肯能源|6.69%|#|蕾奥规划|6.51%|#|星华新材|5.62%|#|捷强装备|4.81%|#|世纪鼎利|4.76%|#|美能能源|3.47%|#|川金诺|3.39%|恒瑞医药所在的化学制药行业,今日主力净流出3.06亿元,行业排名16/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041915192987946692&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041915192987946692&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428570856","title":"直接明牌爆雷!收购遇阻,大牛股高新发展连续两日跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2428570856","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2428570856?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:44","pubTimestamp":1713494668,"startTime":"0","endTime":"0","summary":"10万股民:#¥%……&*+","market":"sg","thumbnail":"https://img3.gelonghui.com/7587f-c14ea83c-cbe0-440a-8a12-0a7ecf303cbe.jpg?guru_height=427&guru_width=640","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/7587f-c14ea83c-cbe0-440a-8a12-0a7ecf303cbe.jpg?guru_height=427&guru_width=640"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/721258","is_publish_highlight":false,"gpt_icon":0},{"id":"2428574293","title":"恒瑞医药4月18日获融资净买入1.22亿元 两市排名第1","url":"https://stock-news.laohu8.com/highlight/detail?id=2428574293","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428574293?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:00","pubTimestamp":1713492009,"startTime":"0","endTime":"0","summary":"4月18日,恒瑞医药获融资净买入1.22亿元,环比上一交易日增加960.41%。其中,融资买入2.15亿元,融资偿还9369万元。融券方面,融券卖出2.63万股,当前融券余量为90.78万股。A股市场共有422股获融资净买入,恒瑞医药净买入额排名第1。股市有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191000188b385a53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191000188b385a53&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428571285","title":"中信海直、恒瑞医药等股获融资净买入超1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428571285","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2428571285?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:36","pubTimestamp":1713490562,"startTime":"0","endTime":"0","summary":"证券时报网讯,据Wind统计显示,4月18日有1813只个股获融资净买入,净买入金额在3000万元以上的有60只。其中,3只融资净买入额超1亿元。中信海直获融资净买入额居首,净买入2.13亿元;融资净买入金额居前的还有恒瑞医药、北汽蓝谷、网宿科技、佰维存储、长安汽车,净买入额分别为1.22亿元、1.16亿元、0.91亿元、0.91亿元、0.85亿元。校对:苏焕文","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190936058b384424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190936058b384424&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428765335","title":"恒瑞医药4月18日遭北向资金减持137.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2428765335","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428765335?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:30","pubTimestamp":1713490209,"startTime":"0","endTime":"0","summary":"4月18日,北向资金减持恒瑞医药137.11万股。截止当日收盘,沪股通共持有恒瑞医药39228.55万股,占流通股6.14%。沪股通减持金额前五个股分别为中信银行、农业银行、紫金矿业、长江电力、建发股份。恒瑞医药近5个交易日下跌5.76%,沪股通累计增持214.19万股;近20个交易日下跌7.87%,沪股通累计增持849.73万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190930478b383fa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190930478b383fa8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428263265","title":"恒瑞医药(600276)2024年一季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2428263265","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428263265?lang=zh_cn&edition=full","pubTime":"2024-04-19 06:21","pubTimestamp":1713478901,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期恒瑞医药发布2024年一季报。根据财报显示,本报告期中恒瑞医药营收净利润同比双双增长。截至本报告期末,公司营业总收入59.98亿元,同比上升9.2%,归母净利润13.69亿元,同比上升10.48%。负债状况方面,公司报告期内合同负债规模环比增幅达632.74%,未完成订单增加,可能的原因有公司交货变慢或者下游需求增强。营收分析方面,公司最新一期年度报表的现金流为正,经营性现金流和利润相匹配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190621488b37aff1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190621488b37aff1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428263115","title":"银华基金马君旗下银华中证创新药产业ETF一季报最新持仓,重仓恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2428263115","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428263115?lang=zh_cn&edition=full","pubTime":"2024-04-19 06:16","pubTimestamp":1713478581,"startTime":"0","endTime":"0","summary":"证券之星消息,4月19日银华基金旗下马君 王帅管理的银华中证创新药产业交易型开放式指数基金公布一季报,近1年净值增长率-31.52%。其中恒瑞医药持仓占比12.01%,为该基金第一大重仓股;详细数据如下:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190618108b37adac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404190618108b37adac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428778596","title":"恒瑞医药:公司第4款产品获得美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2428778596","media":"证券时报·e公司","top":-1,"share":"https://www.laohu8.com/m/news/2428778596?lang=zh_cn&edition=full","pubTime":"2024-04-18 21:03","pubTimestamp":1713445380,"startTime":"0","endTime":"0","summary":"4月18日晚间,恒瑞医药发布公告称,公司近日收到美国食品药品监督管理局的认证函,公司项目注射用SHR-A2102获得美FDA授予的快速通道资格,这是公司第4款产品获得美国FDA快速通道资格认定。此前,SHR-A2102用于治疗晚期实体瘤的临床试验申请已获得美国FDA许可。截至目前,注射用SHR-A2102相关项目累计已投入研发费用约4370万元。而在药物获得FTD后,公司将在后续的药物研发与审评过程中,获得更多与FDA沟通交流的机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041821035879218d05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041821035879218d05&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428856385","title":"“创新药一哥”恒瑞医药2023年业绩止跌回升,仿制药收入滑坡,海外BD道阻且长 | 看财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2428856385","media":"钛媒体","top":-1,"share":"https://www.laohu8.com/m/news/2428856385?lang=zh_cn&edition=full","pubTime":"2024-04-18 17:43","pubTimestamp":1713433394,"startTime":"0","endTime":"0","summary":"但在集采影响逐渐出清及创新药加持下,恒瑞医药2023年交出了一份营收、净利双增的成绩单。2023年财报发布同时,恒瑞医药也公布了一季报数据,营业收入和净利润分别增长9.2%与10.48%。受集采影响,恒瑞医药2021及2022年营收与净利润均出现不同程度下滑。2023年业绩实现止跌回升,并将上升势头延续到了2024年一季度。在经历集采的阵痛后,创新药成为恒瑞医药的重心,并逐渐成为业绩增长的主要推动力。与创新药形成对比的是,仿制药收入滑坡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181743208b356adf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181743208b356adf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428256383","title":"恒瑞医药:2023年度暨2024年第一季度业绩说明会公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2428256383","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428256383?lang=zh_cn&edition=full","pubTime":"2024-04-18 17:42","pubTimestamp":1713433344,"startTime":"0","endTime":"0","summary":"恒瑞医药公告称,已于2024年4月18日发布了公司2023年年度报告及2024年第一季度报告,为便于广大投资者更全面深入地了解公司经营成果、财务状况,公司计划于2024年4月26日上午10:00-11:00举行2023年度暨2024年第一季度业绩说明会,就投资者关心的问题进行交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418174226878fb6eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418174226878fb6eb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428502535","title":"恒瑞医药:子公司获得药物临床试验批准通知书,将开展SHR-3276注射液的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2428502535","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428502535?lang=zh_cn&edition=full","pubTime":"2024-04-18 17:15","pubTimestamp":1713431731,"startTime":"0","endTime":"0","summary":"恒瑞医药 的子公司苏州盛迪亚 生物医药 有限公司近日收到国家药品监督管理局核准签发的关于SHR-3276注射液的《药物临床试验批准通知书》,将于近期开展临床试验。SHR-3276注射液是一种全新的治疗用生物制品,可以增强体内免疫细胞功能,发挥协同增效的抗肿瘤活性。目前,该项目已投入研发费用约1,322万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181719558b3540ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181719558b3540ff&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428366557","title":"恒瑞医药(600276)3月31日股东户数44.05万户,较上期减少5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428366557","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428366557?lang=zh_cn&edition=full","pubTime":"2024-04-18 17:02","pubTimestamp":1713430954,"startTime":"0","endTime":"0","summary":"证券之星消息,近日恒瑞医药披露,截至2024年3月31日公司股东户数为44.05万户,较12月31日减少2.47万户,减幅为5.31%。在化学制药行业个股中,恒瑞医药股东户数高于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.36万户。从股价来看,2023年12月31日至2024年3月31日,恒瑞医药区间涨幅为1.64%,在此期间股东户数减少2.47万户,减幅为5.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418170721878f74c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418170721878f74c2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428557825","title":"恒瑞医药(600276.SH):注射用SHR-A2102获美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2428557825","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428557825?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:57","pubTimestamp":1713430620,"startTime":"0","endTime":"0","summary":"恒瑞医药(600276.SH)发布公告,公司收到美国食品药品监督管理局(简称“FDA”)的认证函,公司项目注射用SHR-A2102获得美国FDA授予快速通道资格,这是公司第4款产品获得美国FDA快速通道资格认定。注射用SHR-A2102为公司自主研发且具有知识产权的靶向Nectin-4的抗体药物偶联物(ADC),其有效载荷是拓扑异构酶抑制剂(TOPi)。多种研究表明Nectin-4在肿瘤中的高表达与肿瘤的发展和不良预后密切相关。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-18/doc-inashaat0649364.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-18/doc-inashaat0649364.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428557831","title":"恒瑞医药(600276.SH):HRS2398缓释片临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2428557831","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428557831?lang=zh_cn&edition=full","pubTime":"2024-04-18 16:53","pubTimestamp":1713430389,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恒瑞医药(600276.SH)发布公告,公司子公司上海恒瑞医药有限公司收到国家药品监督管理局核准签发关于HRS2398缓释片的《药物临床试验批准通知书》,将于近期开展临床试验。HRS2398缓释片为公司自主研发的新型、高效、口服的ATR抑制剂,能够有效抑制ATR激酶活性,加剧DNA双链损伤,抑制细胞增殖,发挥抗肿瘤作用。HRS2398缓释片目前正处于早期临床开发阶段,有潜力作为单一疗法和联合疗法治疗更多肿瘤患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418165505878f59dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418165505878f59dd&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0547},{"period":"1month","weight":-0.0866},{"period":"3month","weight":0.0065},{"period":"6month","weight":-0.0243},{"period":"1year","weight":-0.125},{"period":"ytd","weight":-0.0785}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"14482股","boardName":"医药制造业","registeredCapital":"637900万元","compareEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":-0.0047},{"period":"3month","weight":0.0823},{"period":"6month","weight":0.0276},{"period":"1year","weight":-0.0896},{"period":"ytd","weight":0.0304}],"survey":" 江苏恒瑞医药股份有限公司主营业务涉及药品研发、生产和销售,主要产品是艾瑞昔布片、甲磺酸阿帕替尼片、硫培非格司亭注射液、马来酸吡咯替尼片、卡瑞利珠单抗、甲苯磺酸瑞马唑仑、氟唑帕利胶囊、海曲泊帕乙醇胺片、羟乙磺酸达尔西利片、脯氨酸恒格列净片、瑞维鲁胺片、阿得贝利单抗注射液、磷酸瑞格列汀片、富马酸泰吉利定注射液、林普利塞片、奥特康唑胶囊。报告期内,公司荣获中国医药质量管理协会颁发的“首批无菌药品质量保障企业”荣誉称号、江苏省医药质量管理协会颁发的“江苏省医药行业优秀质量管理企业”荣誉称号;公司“雏鹰QC小组”、“远志QC小组”被评为江苏省医药行业质量管理(QC)发表交流优秀小组。","serverTime":1713598749565,"listedPrice":11.98,"stockholders":"440465人(较上一季度减少5.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}